Do you approve of spending $300 million on HPV vaccination? Yes;Approuvez-vous les 300 M $ pour la vaccination contre le VPH? Oui

Canadian Family Physician

Volumn 54, Issue 2, 2008, Pages

  Steben, Marc ^a,b  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b INSTITUT NATIONAL DE SANTÉ PUBLIQUE DU QUÉBEC   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

CONDYLOMA; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 6; NOTE; PAPILLOMATOSIS; UNSPECIFIED SIDE EFFECT; VACCINATION; VERRUCA VULGARIS; VULVA CANCER; WART VIRUS;

ALPHAPAPILLOMAVIRUS; CANADA; COST OF ILLNESS; COST-BENEFIT ANALYSIS; FEMALE; HEALTH EXPENDITURES; HUMANS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES;

EID: 39649094468     PISSN: 0008350X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (12)

1. HPV Consensus Guidelines Committee. Canadian consensus guidelines on human papillomavirus. JOGC 2007;29(8):1-59. Available from: www.infovph.ca/hpvinfo/pdf/hpv-guideline-full_e.pdf. Accessed 2008 January 8.
2. Clifford GM, Rana RK, Franceschi S, Smith JS, Gough G, Pimenta JM. Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer. Cancer Epidemiol Biomarkers Prev 2005;14:1157-64.
3. Clifford GM, Franceschi M, Diaz M, Munoz N, Villa LL. Chapter 3: HPV type-distribution in women with and without cervical neoplastic diseases. Vaccine 2006;24(Suppl 3):S26-34.
4. Castellsague X, Diaz M, de Sanjosé S, Munoz N, Herrero R, Franceschi S, et al. Worldwide human papillomavirus etiology of cervical adenocarcinoma and its co-factors: implications for screening and prevention. J Natl Cancer Inst 2006;98(5):303-15.
5. Parkin DM, Bray F. Chapter 2: The burden of HPV-related cancers. Vaccine 2006;24(Suppl 3):S11-25.
6. Khan M, Castle PE, Lorincz AT, Wacholder S, Sherman M, Scott DR, et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst 2005;97(14):1072-9.
7. Manhart LE, Koutsky LA. Do condoms prevent genital HPV infection, external genital warts or cervical neoplasia? A meta-analysis. Sex Trans Dis 2002;29(11):725-35.
8. Garland S, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007;356(19):1928-43.
9. Spence A, Goggin P, Franco EL. Process of care failures in invasive cervical cancer: systematic review and meta-analysis. Prev Med 2007;45:93-106.
10. Iskander J. Quadrivalent human papillomavirus vaccine (HPV4): United States post-licensure safety update. Global Advisory Committee on Vaccine Safety, World Health Organization, 12-13 June 2007, Geneva, Switz. Geneva Switz: World Health Organization; 2007.
11. Ollson S, Villa LL, Costa RL, Petta CA, Andrade RP, Malm C, et al. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) TYPES 6/11/16/18 virus-like particle (VLP) vaccine. Vaccine 2007;25(26):4931-9.
12. Brisson M. Estimating the number needed to vaccinate to prevent diseases and death related to human papillomavirus infection. CMAJ 2007;177(5):464-8.